Arcticzymes Technologies Asa · OSL:AZT
Arcticzymes Technologies Asa — Q1 2021 Earnings Presentation
18 slides from Arcticzymes Technologies Asa's earnings presentation, 2021
Slide 1: ArcticZymes Technologies
A ArcticZymes Technologies
Slide 2: Agenda
Agenda 1 Highlights - Q1 2021 2 Business Update 3 Financials 4 Outlook
Slide 3: Highlights
Highlights
Slide 4: Highlights Q1 2021
Highlights Q1 2021 Achieved an outstanding quarterly performance Achieved best ever Successful upscaled quarterly Quarterly growth in the manufacturing performance all market segments process for SAN HQ 40.4 MNOK sales by 100-fold Profitability remains Molecular research strong sales have re- 25.8 M
Slide 5: Business Update
Business Update
Slide 6: Business Updates: Therapeutics and Research & Diagnostics
Business Updates Commercial Segment Sales Therapeutics Research & Diagnostics ✓ 36% quarterly growth compared to Q1 2020 ✓ 176% quarterly growth compared to Q1 2020 ✓ 25% contribution to total Q1 sales ✓ 75% contribution to total Q4 sales ✓ ReiThera has initiated phase 2/3 clinical trails ✓ Molecula
Slide 7: Business Updates: Coronavirus related sales
Business Updates Coronavirus related sales Majority of sales is recurring business rather than one off orders Established long-term busines with numerous companies 41% contribution of total Q1 sales Majority of sales is towards molecular diagnostic testing >90% Quarterly fluctuations to continue but
Slide 8: Business Update: Innovation & Operations
Business Update Innovation & Operations Salt Active Nuclease (SAN) Upscaling Successfully upscaled the manufacturing process of the SAN HQ enzyme Achieved >100-fold increase in fermentation yield Commercially available to our therapeutic Large scale production of SAN HQ customers during Q2 Serves cu
Slide 9: Business Update: Strategic Growth Initiatives
Business Update Strategic Growth Initiatives Main focus have been toward the infrastructure expansion of R&D and Operations Renovation work is underway to modify the infrastructure and install necessary utilities Once complete production and laboratory equipment can AZT´s new production facility bef
Slide 10: Financials
Financials
Slide 11: ArcticZymes Sales Q1 2021
ArcticZymes Sales Q1 2021 Growth continues to be strong Sales per segment Amounts in NOK 1.000' Sales growth of 119% compared to same 50 000 quarter last year 45 000 Therapeutics (SAN) Therapeutics segment (SAN) growth: 10.2 40 000 Research and Diagnostics MNOK (7.5) or increase of 36% 35 000 30 000
Slide 12: ArcticZymes Sales Q1 2021: Covid-19 impact
ArcticZymes Sales Q1 2021 Covid-19 impact is estimated at 41%of quarterly sales Estimated Covid-19 related sales Amounts in NOK 1.000' 18 000 16 000 14 000 12 000 10 000 8 000 6 000 4 000 2 000 - Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 12
Slide 13: 12 Month rolling average sales
12 Month rolling average sales Underlying growth continues across the business Amounts in NOK 1.000' 35 000 30 000 Sales development Sales development ex Covid-19 25 000 20 000 15 000 10 000 5 000 - Q1 2018 Q2 2018 Q3 2018 Q4 2018 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 20
Slide 14: Deliver beyond expectations
ArcticZymes Technologies Deliver beyond expectations Amounts in NOK 1.000' 45 000 119% improvement in sales (MNOK 40.4 vs 18.5) 40 000 Sales EBITDA 194% improvement in EBITDA (MNOK 25.8 vs 9.0) 35 000 30 000 Expenses increased by 4.0 MNOK 25 000 Increase in personnel as we investing in organic growt
Slide 15: Changes in Cash
Cash Flow Final settlement relating to divestment received on 31st March 180 000 90 000 160 000 Net Cash 80 000 Amounts in NOK 1.000' 140 000 Changes in Cash 70 000 120 000 60 000 Changes in Cash 100 000 50 000 Net Cash 163 339 80 000 40 000 140 178 60 000 30 000 40 000 20 000 59 939 48 439 31 580 2
Slide 16: Outlook
Outlook
Slide 17: Outlook 2021 and Beyond
Outlook 2021 and Beyond A new era as a pure enzymes company Performance Focus on topline sales growth New Innovations Profitability Complete portfolio offering of molecular Focus remains on increasing biology enzymes in the next 2-3 years profitability Investment Expanded facilities as well as talen
Slide 18: Thank you Q&A Session
Thank you Q&A Session Annual General Meeting arcticzymes.com 20th May 2021
ArcticZymes Technologies — Q1 2021 Earnings Presentation on 6ix